Literature DB >> 28497563

Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms.

A F Sandes1, M V Gonçalves1, M de L Chauffaille1.   

Abstract

INTRODUCTION: Polycythemia vera (PV) is a disorder characterized by clonal proliferation of myeloid cells and increased red blood cell mass. Recently, the revised 2016 WHO classification of myeloid neoplasms decreased the threshold levels of hemoglobin and hematocrit for the diagnosis of PV. However, the new proposed cutoffs have remarkable overlap with the normal reference values reported and the clinical impact of these new cutoffs has not been widely assessed in the general population.
METHODS: We retrospectively examined 248 839 patients with presumptively normal complete blood cell results, consecutively obtained in an outpatient setting.
RESULTS: The proportion of men with Hb >165 g/L was 5.99%, Hct>49% was 2.4%, and Hb >165 g/dL or Hct>49% was 6.48%, while the proportion of women with Hb >160 g/L was 0.22%, Hct>48% was 0.11%, and Hb >160 g/L or Hct>48% was 0.28%.
CONCLUSION: The isolated use of the proposed Hb/Hct levels as a definer of polycythemia may lead to a substantial increase in unnecessary diagnostic tests. In cases with borderline levels of hemoglobin, the diagnostic workup of PV should only be indicated in the presence of clinical and/or laboratorial features associated with MPN.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  hematocrit; hemoglobin; polycythemia vera

Mesh:

Year:  2017        PMID: 28497563     DOI: 10.1111/ijlh.12686

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

1.  [Retinal manifestation in hematological diseases].

Authors:  M Rehak; N Feltgen; P Meier; P Wiedemann
Journal:  Ophthalmologe       Date:  2018-09       Impact factor: 1.059

2.  Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.

Authors:  Hanneke J C M Wouters; René Mulder; Isabelle A van Zeventer; Jan Jacob Schuringa; Melanie M van der Klauw; Pim van der Harst; Arjan Diepstra; André B Mulder; Gerwin Huls
Journal:  Blood Adv       Date:  2020-12-22

3.  Mutations in the zebrafish hmgcs1 gene reveal a novel function for isoprenoids during red blood cell development.

Authors:  Jose A Hernandez; Victoria L Castro; Nayeli Reyes-Nava; Laura P Montes; Anita M Quintana
Journal:  Blood Adv       Date:  2019-04-23

Review 4.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

5.  Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera.

Authors:  Miguel Piris-Villaespesa; Alberto Álvarez-Larrán; Adolfo Saez-Marín; Claudia Nuñez-Torrón; Gloria Muñoz-Martin; Ricardo Sánchez; Francisco J Del Castillo; Jesús Villarrubia; Javier Lopez-Jimenez; Joaquin Martinez-Lopez; Valentin Garcia-Gutierrez
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

6.  How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey.

Authors:  Rafet Eren; Bahar Funda Sevinçoğlu; Esma Evrim Doğan; Demet Aydın; Nihan Nizam; Naciye Demirel
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.